Introduction
Gaucher's disease (GD, OMIM 230800, 230900, 231000), the inherited deficiency of the lysosomal enzyme glucocerebrosidase (EC 3.2.1.45) presents broad clinical and genetic heterogeneity. 1 Three distinct clinical subtypes are delineated by the absence (type 1) or presence (type 2-acute form, type 3-subacute form) of neurological involvement. 1 Type 2 GD (GD2) is the rarest and the most severe form of GD, with an estimated frequency of 1 in 100 000 to 500 000 live births.
1,2 Classic GD2 (CGD2) is characterized by a symptom-free period, followed by a precocious, rapid neurological brainstem degeneration associated with visceral involvement leading to death by the age of 2 years. 1, 3 The perinatal lethal form of GD (PLGD), a type 2 variant, presents with symptoms at or shortly after birth including neonatal distress, hepatosplenomegaly, ichthyosis, nonimmune hydrops fetalis, arthrogryposis and facial dysmorphism. 4, 5 Although it is often easy to differentiate CGD2 from PLGD, rare reported cases have displayed signs of PLGD with a clinical history of CGD2, suggesting a phenotypic continuum between PLGD and CGD2. Here we report three cases of GD exhibiting a clinical picture consistent with both PLGD and CGD2.
Case report 1 P1, the first child born to nonconsanguineous parents, was admitted at 32 h of life for jaundice associated with hepatosplenomegaly. Pregnancy and delivery were uneventful. Apgar scores were 9 and 10 at 1 and 5 min. Birth weight (BW: 3100 g), length (L: 51 cm) and head circumference (occipitalfrontal circumference, OFC: 35 cm) were appropriate for gestational age. She had normal neurological status and no evidence of dysmorphic features or skin involvement. Biological exams identified cytolysis (alanine aminotransferase/aspartate aminotransferase, ALAT/ASAT: 230/420 U l À1 ), mixed hyperbilirubinemia (total/conjugated bilirubin: 170/82 mg l À1 ), high g-glutamyl transferase (222 U l À1 , versus normal: 71-142 U l À1 ) and thrombocytopenia (55.10 9 per liter). The neonate was discharged at 18 days, after jaundice resolution, but with persistent mild hepatosplenomegaly, cholestasis and mild thrombocytopenia (133.10 9 per liter). Possible alternate diagnoses of biliary atresia, TORCH embryofetopathies, mucopolysaccharidoses and oligosaccharidoses were eliminated by appropriate tests. The growth and psychomotor development were normal until the age of 3 months, she then developed an unexplained weight loss (700 g within 1 month), followed 1 month later by recurrent bronchopneumopathies with rapid increasing visceromegaly. She died at 5 months of age from respiratory distress despite intensive resuscitation. No overt neurological signs were noted in this patient until death. growth retardation (BW: 2500 g, L: 45 cm, OFC: 33.5 cm), intense jaundice associated with massive hepatosplenomegaly and cutaneous hemorrhagic syndrome. The child had hypertelorism, flat nasal bridge and a small nose. Venous collateral circulation and ascites were also noted. Neurological status and skin were normal. Biologic investigations identified cholestasis (total/ conjugated bilirubin: 495/320 mg l À1 ), cytolysis (ALAT/ASAT: 514/274 U l À1 ), hepatic failure (prothrombin time, PT: 60 s instead of the normal 12 s) and thrombocytopenia (34.10 9 per liter). Biological stigmata of erythrophagocytosis syndrome were also established (hyponatremia: 125 mmol l À1 , hypertriglyceridemia: 4.6 g l À1 , elevated ferritinemia: 806 ng ml À1 and lactate dehydrogenase: 1237 U l À1 ). Bone marrow aspiration failed to prove hemophagocytosis or identification of Gaucher cells. After a vitamin K injection and multiple platelet transfusions, we observed progressive, partial improvement of liver function (PT: 15/13 s) and thrombocytopenia (78.10 9 per liter). At age 2 months, ponderal gain and cranial growth were normal for age, 4800 g and 42 cm, respectively. No neurological symptoms or signs were noted until this date. Death occurred at home, at 4 months of age after uncontrollable digestive tract bleeding. The diagnosis of GD was based on low activity of glucocerebrosidase in leukocytes (4 nmol per h per mg protein versus 56 in controls).
Case report 3 P3, a male patient, was the third child to consanguineous parents. His sister had died at 40 days suddenly after a neurologic degradation with opisthotonus, ichthyosis and cachexia. With P3, the pregnancy was uneventful. Apgar scores were 9 of 10 at 1 and 5 min. BW was 3850 g, L was 50 cm and head circumference was 32 cm. Generalized ichthyosiform skin was noted at 3 days of age, when he was admitted for suspected maternofetal infection. At 1 month he developed seizures with limb and axial hypertonia.
Physical examination at 2 months noted micrognathism, macroglossia, gingival hypertrophy, moderate hepatosplenomegaly, no eye pursuit, tetrapyramidal syndrome with opisthotonus and permanent stridor. Swallowing impairment necessitated gastric tube feeding. There was neither interaction with stimuli nor psychomotor development.
Biological investigations identified normochromic anemia (8.5 g per 100 ml), thrombocytopenia (96.10 9 per liter), cholestasis (g-glutamyl transferase: 262 U l À1 , alkaline phosphatase: 885 U l À1 ) and high ferritinemia (750 ng ml À1 ). No visual evoked potentials were recorded and generalized spikes were found on electroencephalography. The clinical picture worsened 1 month later with repetitive aspiration pneumopathies, failure to thrive, progressive microcephaly (À2.75 s.d.) and an event of myoclonic seizures. Death occurred at 4 months, after severe neurological deterioration and recurrent apneas. Low activity of glucocerebrosidase on leukocytes (2 nmol per hour per mg protein versus 28 in controls) confirmed the diagnosis of GD.
Discussion
Gaucher's disease encompasses a continuum of phenotypes, most of them fit the criteria for one classic phenotype or the other and some do not. Our patients showed overlap clinical features between the CGD2 and its variant PLGD.
As it was for our patients, the prenatal history was unremarkable in all but one of the 76 patients with CGD2 reviewed by Mignot et al. At the opposite, a nonimmune hydrops fetalis (NIHF), fetal demise, prematurity and neonatal distress complicates frequently pregnancies in the PLGD group. [4] [5] [6] When hydrops is present, the fetus dies either in utero or within 2 days after premature delivery; otherwise infants presented with neonatal distress requiring resuscitation and die within 3 months after a rapidly neurological degradation. 4 Among the main non-neurological signs, splenomegaly at birth is a major sign of PLGD. 4, 6 It was seen in two of our patients, but was associated with signs of brainstem involvement in only 6 of the 76 patients with CGD2. 3 Clinical expression of liver involvement observed in P1 and P2 were rarely reported in the CGD2 whereas it was a likely cause of death in PLGD. [3] [4] Jaundice and deficiency of clotting factors were present in three of the eight French PLGD cases. 3 Cormand et al. 7 reported two Spanish cases showing hepatosplenomegaly, ascites and cholestatic jaundice at birth and who died before 4 months of age without any neurological symptoms. Barbier et al. 8 , and Holleran et al. 9 reported each one, a case of CGD2 presenting at birth with cholestatic jaundice, hepatosplenomegaly and thrombocytopenia that persisted isolated until development of neurological signs. The fatal digestive bleeding that occurred in P2 may be related to portal hypertension that has been rarely reported in GD. 8, 10, 11 Failure to thrive observed in our three patients was a precocious and almost constant sign in the French cohort of CGD2. 3 This feature results mainly not only from neurologic feeding difficulties but also from the wasting syndrome that has been proven in patients with neuropathic forms of GD and that we suspected in P1. 3 Lung disease, the most severe non-neurological feature of CGD2 may be attributed to isolated or combined diffuse lung infiltration with Gaucher cells or to repeated aspirations. 3 Early oropharyngeal dysmotility was highly suspected in P3 and his sister but only suspected in P1 because recurrent pneumonias occurred in the absence of neurological degeneration.
Icthyosis, a striking dermatologic feature of PLGD was observed at birth in two of our patients and in only three additional cases of CGD2. 3 Furthermore, facial dysmorphism, seen in two of our patients, was reported in 33% of PLGD group versus only one patient with possible CGD2. 3, 4 Neurological signs in CGD2 include hyperextension of the neck, swallowing impairment, peripheral hypertonia and strabismus; all reflecting progressive brainstem degeneration. Apnea, a late feature, appeared at a mean age of 7.7 months in 61% of CGD2 patients. 3 Myoclonic epilepsy is rare and emerges when the patients live long enough. P3 displayed almost of all these signs precociously in the first month of life with rapidly progressive course such as described in PLGD. 4 Table 1 shows differential features reported in both CGD2 and PLGD.
Conclusion
Atypical presentation of early GD surely makes phenotypic classification difficult, but it does not present difficulty regarding genetic counseling or therapeutic management because inheritance is the same and neither phenotype is a candidate for curative treatments. PLGD is still a poorly known condition among obstetricians and neonatologists who should evaluate GD in the differential diagnosis of congenital ichthyosis and NIHF presenting prenatally or at birth. 
